1.科技部重点研发计划子课题，2022YFA0806401，测绘成体菌群及代谢产物在不同生理/病理状态下的动态变化规律，2022-12至2027-12，783万元，在研，主持；

2.国家自然科学基金委员会，面上项目，81972137，有氧运动通过GLP-1及其下游核受体及氧化应激信号改善小鼠心梗模型心功能康复，2020-01至2023-12 , 55万元，在研，主持；

3.国家自然科学基金委员会，面上项目，81770792，GLP-1受体激动剂通过FGF21/FGFR1/β-Klotho途径调节肥胖小鼠脂肪组织神经酰胺代谢异常的机制研究，2018-01至 2021-12, 56万元，结题，主持；

4.  北京市医管局重点专科扬帆计划，ZYLX202106，2021-01至2023-12，100万元，主持。

1、  Sun L#, Xie C#, Wang G#, Wu Y#,Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X,Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J,Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C*. Gut microbiota andintestinal FXR mediate the clinical benefits of metformin. Nat Med.2018;24(12):1919-1929. (IF:82.9, Q1)

2、  Wang K#, Zhang Z#, Hang J#, Liu J#, Guo F, Ding Y, Li M, Nie Q, Lin J, Zhuo Y, Sun L, Luo X, Zhong Q, Ye C, Yun C, Zhang Y, Wang J, Bao R, Pang Y, Wang G*, Gonzalez F*, Lei X*, Qiao J*, Jiang C*, Microbial-host-isozyme analyses reveal microbial DPP4 as a potentialantidiabetic target. Science, 2023; 381(6657):eadd5787. (IF:56.9, Q1)

3、 Liu J, Wang Y, An H, Liu J, Wei J, Wang H, Wang G*.Correlation between arterial stiffness and coronary flow velocity reserve insubjects with pulse wave velocity >1400 cm/s. Clin Exp Hypertens.2016;38(1):89-94. (IF: 12.3, Q1)

4、 Zhang H#, Huang Y#, Chen S, Tang C, Wang G*, Du J*, Jin H*.Hydrogen sulfide regulates insulin secretion and insulin resistance in diabetesmellitus, a new promising target for diabetes mellitus treatment? A review. JAdv Res. 2021;27:19-30. (IF:10.7, Q1)

5、  Liu J, Xu Y, Hu Y, Wang G*. Therole of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fattyliver disease and implications for therapy. Metabolism. 2015;64(3):380-390. (IF:9.8, Q1)

6、  Yu J#, Jin N#, Wang G*, ZhangF, Mao J, Wang X. Peroxisome proliferator-activated receptor gamma agonistimproves arterial stiffness in patients with type 2 diabetes mellitus andcoronary artery disease. Metabolism. 2007;56(10):1396-1401. (IF: 9.8, Q1)

7、  Wang G#, Wei J#, Guan Y, Jin N, Mao J, Wang X*. Peroxisomeproliferator-activated receptor-gamma agonist rosiglitazone reduces clinicalinflammatory responses in type 2 diabetes with coronary artery disease aftercoronary angioplasty. Metabolism. 2005;54(5):590-597. (IF: 9.8, Q1)

8、  Sun W#, Wang G#, Zhang ZM, ZengXK, Wang X*. Chemokine RANTES is upregulated in monocytes from patients withhyperhomocysteinemia. Acta Pharmacol Sin. 2005;26(11):1317-1321. (IF: 8.2, Q1)

9、  Liu J, Wang G*, Jia Y, Xu Y*.GLP-1 receptor agonists: effects on the progression of non-alcoholic fattyliver disease. Diabetes Metab Res Rev. 2015;31(4):329-335. (IF: 8.0, Q1)

10、 Wang G#*, Liu J#, Yang N, Hu Y, Zhang H, Miao L, YaoZ, Xu Y. Levothyroxine treatment restored the decreased circulating fibroblastgrowth factor 21 levels in patients with hypothyroidism. Eur J Intern Med.2016;31:94-98. (IF: 8.0, Q1)

11、 Hu Y#, Liu J#, Zhang H, Xu Y, Hong T, WangG*. Exenatide treatment decreases fasting fibroblast growth factor 21levels in patients with newly diagnosed type 2 diabetes mellitus. DiabetesMetab. 2016;42(5):358-363. (IF: 7.2, Q1)

12、 Wang G, Mao JM*, Wang X, Zhang FC. Effect ofhomocysteine on plaque formation and oxidative stress in patients with acutecoronary syndromes. Chin Med J (Engl). 2004;117(11):1650-1654. (IF: 6.1, Q1)

13、 Zhou L#, Wang Y#, Su J, An Y, Liu J, WangG*, Vitamin D Deficiency Is Associated with Impaired Sensitivity toThyroid Hormones in Euthyroid Adults, Nutrients, 2023, 15(17):3697 (IF:5.9,Q1)

14、 Sun H#, Zhu W#, Liu J, An Y, Wang Y, WangG*, Reduced sensitivity to thyroid hormones is associated with highremnant cholesterol levels in Chinese euthyroid adults, J Clin EndocrinolMetab. 2022. 108(1):166-174 (IF:5.8, Q1)

15、 Ding X, Wang Y, Liu J*, Wang G*,Impaired sensitivity to thyroid hormones is associated with elevatedhomocysteine levels in the euthyroid population. J Clin Endocrinol Metab. 2022.107(9):e3731-e3737 (IF: 5.8, Q1)

16、 Li X, Liu J, Zhou B, Li Y, Wu Z, Meng H*, WangG*. Sex Differences in the Effect of Testosterone on Adipose TissueInsulin Resistance from Overweight to Obese Adults. J Clin Endocrinol Metab.2021. 106(8): 2252-2263 (IF: 5.8, Q1)

17、 Fan H, Sun X, Zhang H, Liu J, Zhang P, Xu Y,Pan Q, Wang G*. Effect of Metformin on Fibroblast GrowthFactor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes. DiabetesTechnol Ther. 2016;18(3):120-126. (IF: 5.4, Q1)

18、 Wang G, Dai J, Mao J, Zeng X, Yang X, Wang X*.Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretionfrom monocytes in patients with hyperhomocysteinemia. Atherosclerosis.2005;179(2):395-402. (IF: 5.3, Q2)

19、 Wen Y#, Zhang H#, Yang N, Gao X, Chen Z, LiuJ*, Wang G*, Serum IL-27 levels increase in subjects withhypothyroidism and are negatively correlated with the occurrence ofnonalcoholic fatty liver disease, Front Endocrinol (Lausanne). 2023; 14:1173826.(IF:5.2, Q1)

20、Wang J, Sun H, Wang Y, An Y, Liu J, Wang G*, Glucosemetabolism status modifies the relationship between lipoprotein(a) and carotidplaques in individuals with fatty liver disease, Front Endocrinol (Lausanne).2022; 13:947914. (IF:5.2, Q1)

21、Liu J, Chang X, Wang Q, Ding X, Jiang T*, Wang G*, Magneticresonance T1-mapping quantitatively assesses the severity of thyroiddestruction in patients with autoimmune thyroiditis. Front Endocrinol(Lausanne). 2022; 13:1028588. (IF: 5.2, Q1)

22、Ding X, Chang X, Wang J, Bian N, An Y, Wang G*, Liu J*,Serum Metrnl levels are decreased in subjects with overweight or obesity andare independently associated with adverse lipid profile. Front Endocrinol(Lausanne). 2022; 13:938341. (IF: 5.2, Q1)

23、Wang J#, Sun Q#, An Y, Liu J, Song L*, Wang G*, Theassociation of remnant cholesterol (RC) and interaction between RC and diabeteson the subsequent risk of hypertension, Front Endocrinol (Lausanne). 2022; 13:951635. (IF: 5.2, Q1)

24、Sun H#, Chang X#, Bian N, An Y, Liu J, Leng S*, Wang G*, Adipose tissueinsulin resistance is postively associated with serum uric acid levels andhyperuricemia in Northern Chinese adults, Front Endocrinol (Lausanne). 2022;13:835154.(IF: 5.2, Q1)

25、Zhang L, Hu Y, An Y, Wang Q, Liu J*, Wang G*, The Changes ofLipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients WithType 2 Diabetes. Front Endocrinol (Lausanne). 2022;13:677202. (IF: 5.2, Q1)

26、 Liu J, Chen Z, Liu M, Jia Y, Yao Z, WangG*. Levothyroxine Replacement Alleviates Thyroid Destruction inHypothyroid Patients With Autoimmune Thyroiditis: Evidence From a Thyroid MRIStudy. Front Endocrinol (Lausanne). 2019;10:138. (IF: 5.2, Q1)

27、 Liu J, Duan Y, Fu J, Wang G*.Association Between Thyroid Hormones, Thyroid Antibodies, and CardiometabolicFactors in Non-Obese Individuals With Normal Thyroid Function. Front Endocrinol(Lausanne). 2018;9:130. (IF: 5.2, Q1)

28、 Liu J, Fu J, Duan Y, Wang G*.Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal ofAntithyroid Drugs in Patients with Graves' Disease. Front Endocrinol(Lausanne). 2017;8:258. (IF: 5.2, Q1)

29、 He L#, Zeng H#, Li F, Feng J, Liu S, Liu J,Yu J, Mao J, Hong T, Chen AF, Wang X, Wang G*. Homocysteineimpairs coronary artery endothelial function by inhibiting tetrahydrobiopterinin patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab.2010;299(6):E1061-E1065. (IF: 5.1, Q1)

30、 Liu J#, Zhou L#, An Y, Wang Y*, Wang G*,The atherogenic index of plasma: A novel factor more closely related tonon-alcoholic fatty liver disease than other lipid parameters in adults, FrontNutr, 2022, 9:954219. (IF: 5.0, Q2)

31、 An Y#, Lin Y, Bian N, Ding X, Chang X, LiuJ*, Wang G*, Different Interactive Effects of Metformin andAcarbose with Dietary Macronutrient Intakes on Type 2 Diabetes MellitusPatients Novel Findings from the MARCH Randomized Trial in China. Front Nutr,2022, 9:861750. (IF: 5.0, Q2)